Summary
An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102
Conditions
Phenylketonuria, PAH Deficiency
Recruitment Status
Enrolling by invitation
Detailed Description
This Long-Term Follow Up Study will evaluate the safety and efficacy of PKU Subjects with PAH Deficiency Previously Administered HMI 102. Subjects will have already received a single dose of HMI-102 administered intravenously
Eligibility Criteria
Inclusion Criteria:
Subject was previously administered HMI 102.
Subject is able to understand the purpose and risks of the study and is willing to provide informed consent.
Subject is able to comply with all study procedures and long-term follow-up.
Exclusion Criteria:
Participation in the study is not in the subject's best interest, in the opinion of the Investigator.
Intervention
Intervention Type
Intervention Name
Genetic
HMI-102
Gender
All
Min Age
18 Years
Max Age
55 Years
Download Date
June 30, 2022
Principal Investigator
N/A
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team: